Fred Hutch Cancer Center

Fred Hutch Cancer Center

Fred Hutch Cancer Center was established in 1975 as an independent nonprofit focused on adult cancer research and treatment. Thomas J. Lynch Jr. serves as president and director. The institution receives major philanthropic support from the Bezos Family and Stuart and Molly Sloan. The endowment deploys capital across private equity, venture capital, and hedge funds while maintaining a 1.64 percent private-equity allocation. Confirmed holdings include positions in Affini-T Therapeutics and Ensoma. Spin-offs originating from the center include Juno Therapeutics, Adaptive Biotechnologies, Nohla Therapeutics, and Faraday Pharmaceuticals. Geographic reach centers on the United States with additional research operations in Uganda and South Africa. The organization employs 6066 people and holds direct title to the 15-acre South Lake Union campus plus the 1165 Eastlake Avenue East building. It maintains a 70 percent joint-venture interest in the Lake Union Steam Plant and Earl Davie Building through partnerships with Alexandria Real Estate Equities. The Fred Hutch Foundation serves as the primary fundraising vehicle and reported $147.1 million in estimated giving. In August 2024 the center sponsored Obliteride to support cancer-research fundraising. Fred Hutch structures its investment and real-estate activities through direct ownership and joint ventures rather than external fund commitments. This approach allows the center to control campus expansion while generating licensing revenue from an intellectual-property portfolio that exceeds 84 active patents.